Such discoveries have enhanced researchers’ ability to enrich study populations with patients who are likely to benefit from the drug, while sparing from any possible side effects of exposure those patients who are unlikely to benefit. Enrichment thus enables researchers to strengthen clinical trials’ “statistical power,” that is, the probability of detecting differences, if any exist, between study groups.